Featured

Dec 11 2024 Taiwan Healthcare+ Expo: Innovations in Five Key Industries read more »
Dec 08 Beam shares results from seven patients who received gene-edited sickle cell therapy read more »
Nov 14 Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies read more »
News
Dec 11 Sanofi's Combo Vaccine For Flu And COVID-19 Gets FDA Fast Track read more »
Dec 11 A Strategy for Reproducible Protein Quantitation in Gene Therapies Using Ion Mobility Spectrometry read more »
Dec 11 A new class of antivirals could help prevent future pandemics read more »
Dec 10 Gene Therapy Reverses Effects of Heart Failure and Restores Heart Function in Minipigs read more »
Dec 10 Undergoing Stem Cell Transplant for Sickle Cell Disease in Childhood Improves Quality of Life a Decade Later read more »
Dec 10 Global Veterinary Vaccines Market is Predicted to Cross USD 16 Billion by 2030 read more »
Dec 08 Lymphoma Immunotherapy Enhanced by Enzyme Inhibitor In Preclinical Model, Prompting Pilot Clinical Studies read more »
Articles
Dec 11 Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia read more »
Dec 11 Using artificial intelligence to develop gene therapy for the lungs read more »
Dec 11 Erratum for the Review "Engineering CAR-T therapies for autoimmune disease and beyond" by E. P. English et al. read more »
Dec 10 Regulating chromatin assembly read more »
Dec 09 Intracisternal vs intraventricular injection of AAV1 result in comparable, widespread transduction of the dog brain read more »
Dec 09 Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE